Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
– Profiling of IL-38 mRNA in over 60 cancer types revealed notably high frequency (60-80%) of IL-38 expression in select solid tumor sub-types of high unmet clinical need –
– Collaboration with Fox Chase Cancer Center to directly confirm IL-38 protein expression in patients –
– Anticipated IND filing in 2H 2022 –
Comments are closed.